Cardio Catch-Up: Medtronic Still Has Work To Do On RDN After FDA Advisory Panel

 
• By Reed Miller

FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.

blood pressure
• Source: Shutterstock

Medtronic’s long struggle to launch its Symplicity Spyral renal denervation (RDN) technology on the US market is not going to get any easier following a mixed review by the US Food and Drug Administration’s circulatory system devices advisory panel.

The panel considered the company's premarket approval application (PMA) for Symplicity Spyral on 23 August, one day after it considered a similar application from ReCor Medical for its Paradise...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation